MarketLens
Sign Up

What Just Happened with Praxis's Vormatrigine Program

5 months ago
SHARE THIS ON:

What Just Happened with Praxis's Vormatrigine Program

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven shares fell more than 13% in premarket trading after the U.S. FDA imposed a partial clinical hold on its experimental epilepsy drug, pausing new patient enrollment following rodent findings.
Stock News•1 months ago

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial

EpilepsyGTx and Viralgen launched a collaboration to advance an AAV gene therapy program for refractory epilepsy ahead of a first-in-human trial, potentially accelerating clinical timelines and manufa...
Stock News•2 months ago

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines is preparing potential commercial launches for ulixacaltamide and relutrigine, with both NDAs under FDA review, positioning the company for near-term market entry if approva...

Breaking News

View All →

Top Headlines

View More →
Stock News•26 minutes ago

Google parent Alphabet suffers nearly $500B Wall Street wipeout amid AI spending fears

Stock News•53 minutes ago

Amazon the Latest Mag 7 to Miss Q3 Estimates

Stock News•1 hour ago

20 Years of S&P 500 History Show: This Simple Strategy Is Only 8.3% Less Than "Perfect"

Stock News•1 hour ago

Microsoft Q1: Capex Shouldn't Scare You Due To Free Cash Flow

Stock News•1 hour ago

Microsoft Took The Balanced Approach To AI - Now It's The King